Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Radiofrequency Can Treat Benign Liver Tumors

By HospiMedica staff writers
Posted on 28 Aug 2006
Following extensive patient studies that started in 1999, Chinese researchers have concluded that ultrasound-guided radiofrequency ablation (RFA) can be an efficient and safe method for the treatment of hepatic primary cysts. More...


According to Dr. Du Xi-Lin, from the Tang Du Hospital, Fourth Military Medical University (Xian, China), ultrasound-guided RFA has many merits compared with other methods. "All procedures are under local anesthesia. A laparotomy is not needed so there is minimal injury and pain,” he stated, adding that in most patients, one year after the procedure there was no significant recurrence.

"RFA gives doctors and patients a new choice to cure hepatic cysts. It is an outstanding therapy that induces localized coagulation of the tumor by creating resistive ionic heating through the electrode.” Dr. Du noted that RFA is a relatively new procedure for treatment of hepatic tumors not amenable to removal.

B-ultrasound-guided RFA, using the RF-2000 system of RadioTherapeutics Corp. (Mountain View, CA, USA) and the 450 ultrasound system of Hitachi (Tokyo, Japan), was performed on 29 patients: 12 males and 17 females. The mean age was 47.2. Patients were diagnosed using computed tomography (CT) or magnetic resonance imaging (MRI). Tumors were single or multiple: eight patients had a single tumor, 21 had multiple tumors.

During the RFA procedure, patients had no significant discomfort. For those with tumors larger than 10 cm or multiple tumors, there was some sweating, local distending, and fever, but no significant changes of liver function. In three cases, serum bilirubin increase occurred but became normal after a week.

For 34 cysts with < 5 cm diameter, the tumors were ablated completely, with no recurrence after three months. For 21 cysts 5-10 cm, the decrease of tumor volume was > 70%. For eight cysts with > 10 cm diameter, the decrease of tumor volume was > 60%. Six cysts had tumor shrinkage up to 80% and fibering. Two cysts had a smaller increase at one month after the RF procedure. In subsequent checks six and 12 months after RFA, tumors less than 10 cm in diameter were fully ablated.



Related Links:
Fourth Military Medical University

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.